MeVis Medical Solutions AG Lowers 2024/2025 Revenue Forecast to €16.5-€17.0M, EBIT Expected to Decline to €3.0-€3.5M

Reuters

Aug 21

MeVis Medical Solutions AG Lowers 2024/2025 Revenue Forecast to €16.5-€17.0M, EBIT Expected to Decline to €3.0-€3.5M

MeVis Medical Solutions AG has adjusted its forecast for the 2024/2025 fiscal year, based on preliminary figures for the first ten months. The company now expects revenue to decline slightly to a range of €16.5 million to €17.0 million, down from the previous forecast of €17.0 million to €17.5 million. Additionally, earnings before interest and taxes $(EBIT)$ are anticipated to decline to between €3.0 million and €3.5 million, compared to the earlier forecast of €3.5 million to €4.0 million. The adjustment is attributed to license sales being below expectations, which cannot be offset by maintenance revenues and other revenues. MeVis Medical Solutions AG continues to be a leading provider of medical imaging software.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeVis Medical Solutions AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2187294_en), on August 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2561494928"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561494928\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561494928?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-21 23:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561494928","market":"nz","top_or_hot":-1,"title":"MeVis Medical Solutions AG Lowers 2024/2025 Revenue Forecast to €16.5-€17.0M, EBIT Expected to Decline to €3.0-€3.5M","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MeVis Medical Solutions AG Lowers 2024/2025 Revenue Forecast to €16.5-€17.0M, EBIT Expected to Decline to €3.0-€3.5M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MeVis Medical Solutions AG has adjusted its forecast for the 2024/2025 fiscal year, based on preliminary figures for the first ten months. The company now expects revenue to decline slightly to a range of €16.5 million to €17.0 million, down from the previous forecast of €17.0 million to €17.5 million. Additionally, earnings before interest and taxes <a href=\"https://laohu8.com/S/EBIT\">$(EBIT)$</a> are anticipated to decline to between €3.0 million and €3.5 million, compared to the earlier forecast of €3.5 million to €4.0 million. The adjustment is attributed to license sales being below expectations, which cannot be offset by maintenance revenues and other revenues. MeVis Medical Solutions AG continues to be a leading provider of medical imaging software.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeVis Medical Solutions AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2187294_en), on August 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MeVis Medical Solutions AG Lowers 2024/2025 Revenue Forecast to €16.5-€17.0M, EBIT Expected to Decline to €3.0-€3.5M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeVis Medical Solutions AG Lowers 2024/2025 Revenue Forecast to €16.5-€17.0M, EBIT Expected to Decline to €3.0-€3.5M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-21 23:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MeVis Medical Solutions AG Lowers 2024/2025 Revenue Forecast to €16.5-€17.0M, EBIT Expected to Decline to €3.0-€3.5M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MeVis Medical Solutions AG has adjusted its forecast for the 2024/2025 fiscal year, based on preliminary figures for the first ten months. The company now expects revenue to decline slightly to a range of €16.5 million to €17.0 million, down from the previous forecast of €17.0 million to €17.5 million. Additionally, earnings before interest and taxes <a href=\"https://laohu8.com/S/EBIT\">$(EBIT)$</a> are anticipated to decline to between €3.0 million and €3.5 million, compared to the earlier forecast of €3.5 million to €4.0 million. The adjustment is attributed to license sales being below expectations, which cannot be offset by maintenance revenues and other revenues. MeVis Medical Solutions AG continues to be a leading provider of medical imaging software.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeVis Medical Solutions AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2187294_en), on August 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VREX","symbol_name":"Varex Imaging Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250821:nNDLc0Q9f:1","article_id":"2561494928","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561494928","pubTimestamp":1755791139,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MeVis Medical Solutions AG has adjusted its forecast for the 2024/2025 fiscal year, based on preliminary figures for the first ten months. The company now expects revenue to decline slightly to a range of 16.5 million to 17.0 million, down from the previous forecast of 17.0 million to 17.5 million. Additionally, earnings before interest and taxes  are anticipated to decline to between 3.0 million and 3.5 million, compared to the earlier forecast of 3.5 million to 4.0 million. The adjustment is attributed to license sales being below expectations, which cannot be offset by maintenance revenues and other revenues. MeVis Medical Solutions AG continues to be a leading provider of medical imaging software.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or l","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"VREX":"Varex Imaging Corporation"},"translate_title":"MeVis Medical Solutions AG将2024/2025年收入预测下调至1650万至1700万欧元，息税前利润预计将降至300万至350万欧元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VREX":0.9},"content_text":"MeVis Medical Solutions AG Lowers 2024/2025 Revenue Forecast to €16.5-€17.0M, EBIT Expected to Decline to €3.0-€3.5M\n    \n\n        MeVis Medical Solutions AG has adjusted its forecast for the 2024/2025 fiscal year, based on preliminary figures for the first ten months. The company now expects revenue to decline slightly to a range of €16.5 million to €17.0 million, down from the previous forecast of €17.0 million to €17.5 million. Additionally, earnings before interest and taxes $(EBIT)$ are anticipated to decline to between €3.0 million and €3.5 million, compared to the earlier forecast of €3.5 million to €4.0 million. The adjustment is attributed to license sales being below expectations, which cannot be offset by maintenance revenues and other revenues. MeVis Medical Solutions AG continues to be a leading provider of medical imaging software.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeVis Medical Solutions AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2187294_en), on August 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}